Klearman Micki 4

4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023

Form 4

Period: 2023-07-24

Director

Transactions

Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 total
Exercise: $2.28Exp: 2031-06-27→ Common Stock (26,000 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 total
Exercise: $2.28Exp: 2032-06-15→ Common Stock (26,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−52,000→ 0 total
Exercise: $5.94Exp: 2031-05-31→ Common Stock (52,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 total
Exercise: $5.59Exp: 2031-06-27→ Common Stock (26,000 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+52,000→ 52,000 total
Exercise: $2.28Exp: 2031-05-31→ Common Stock (52,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 total
Exercise: $4.80Exp: 2032-06-15→ Common Stock (26,000 underlying)

Footnotes (3)

[F1]One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of June 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
[F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
[F3]Fully vested and exercisable.

Documents

1 file